Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: A suspension assembly (10) comprising: a support member (12) for supporting an item; an elongate suspension article (14) defining a securing opening (30); and a securing device (16) on the support member (12). The support member (12) defines an aperture (38) through which the suspension article (14) can be inserted. The securing device (16) has a securing member (68) movable across the aperture (38) between a securing position and a non-securing position. The securing member (68) is receivable through the securing opening (30) in the suspension article (14) to secure the support member (12) to the suspension article (14) when the suspension article (14) is received through the aperture (38) and the securing member (68) is in the securing position.

Abstract: A suspension assembly comprising: a support member for supporting an item; an elongate suspension article defining a securing opening; and a securing device on the support member. The support member defines an aperture through which the suspension article can be inserted. The securing device has a securing member movable across the aperture between a securing position and a non-securing position. The securing member is receivable through the securing opening in the suspension article to secure the support member to the suspension article when the suspension article is received through the aperture and the securing member is in the securing position.

Abstract: A connecting apparatus comprises a support member (12) and a fastening arrangement (24) to secure the support member (12) to an elongate member (14). The fastening arrangement (24) comprises a holding component (26) for holding the elongate member (14). The holding component (26) defines a through hole (28) for receiving the elongate member (14) through the holding component (26). The through hole (28) has a holding region (36) and a release region (38). The holding component (26) has cooperating formations at the holding region (36) to cooperate with corresponding formations on the elongate member (14). The holding component (26) is movable relative to the support member (12) between a holding position and a released position.

Abstract: The present invention relates to attenuated African Swine Fever viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever. The invention also relates to EP402R proteins of African Swine Fever virus comprising particular amino acid substitutions, as well as polynucleotides encoding such proteins and African Swine Fever viruses comprising such proteins.

Abstract: A connecting apparatus comprises a support member (12) and a securing arrangement (16) to secure the support member (12) to an elongate member (14). The securing arrangement (16) comprises a clamping arrangement comprising a body (36) having an internal converging wall arrangement (42). The converging wall arrangement (42) defines a passage (44) for receiving the elongate member (14) therethrough. The clamping arrangement further includes a clamping member (48) in the passage (44). The clamping member (48) is movable along the passage (44) in a clamping direction to clamp the elongate member (14).

Abstract: Disclosed herein are a catheter assembly and method of applying a catheter assembly. In an example, the catheter assembly can include a catheter body and frame member extending between proximal and distal portions, the frame member having a first mechanical characteristic, and a floating sleeve coupled around the frame member and extending between the proximal and distal portions, the floating sleeve having a second mechanical characteristic different than the first mechanical characteristic. The floating sleeve can include at least one floating segment and one or more anchor segments along the catheter body. The at least one floating segment of the floating sleeve can be moveable relative to the frame member, and the one or more anchor segments of the floating sleeve can be interconnected with the frame member.

Abstract: Disclosed herein are a catheter assembly and method of applying a catheter assembly. In an example, the catheter assembly can include a catheter body and frame member extending between proximal and distal portions, the frame member having a first mechanical characteristic, and a floating sleeve coupled around the frame member and extending between the proximal and distal portions, the floating sleeve having a second mechanical characteristic different than the first mechanical characteristic. The floating sleeve can include at least one floating segment and one or more anchor segments along the catheter body. The at least one floating segment of the floating sleeve can be moveable relative to the frame member, and the one or more anchor segments of the floating sleeve can be interconnected with the frame member.

Abstract: Stiffening apparatus (FIG. 1) A stiffening apparatus (10) for use with a suspension assembly (12) is disclosed. The stiffening apparatus (10) comprises a suspension assembly (68) configured for receiving a first part of the suspension assembly (12). The stiffening apparatus (10) further includes a holder (70) extending transverse to the suspension assembly (68). The holder (70) is configured for receiving a second part of the suspension assembly (12). The holder (70) secures the stiffening apparatus (10) to the suspension assembly (12).

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.

Abstract: The present invention relates to attenuated African Swine Fever viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever.

Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.

Abstract: Discussed herein are various embodiments related to a catheter assembly. The catheter assembly can include a catheter body extending between a proximal portion and a distal portion. The catheter body can include a sleeve and a hypotube, connected by at least one bond site, and separated by a floating gap. The hypotube can include at least one flow opening extending from the hypotube lumen to a stagnation zone, configured to permit flow between the stagnation zone and the hypotube lumen.